NeoGenomics
NEO
#5115
Rank
$1.57 B
Marketcap
$12.17
Share price
0.41%
Change (1 day)
-32.43%
Change (1 year)

P/E ratio for NeoGenomics (NEO)

P/E ratio as of December 2025 (TTM): -13.8

According to NeoGenomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.8295. At the end of 2024 the company had a P/E ratio of -26.6.

P/E ratio history for NeoGenomics from 2004 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-26.6
2022-7.97-98.6%
2021-569-131.69%
2020> 1000329.49%
2019418111.36%
2018198-412.39%
2017-63.3188%
2016-22.0-87.44%
2015-175-192.61%
2014189161.31%
201372.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
RadNet
RDNT
-386 2,691.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Psychemedics
PMD
-3.75-72.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Quest Diagnostics
DGX
21.3-254.14%๐Ÿ‡บ๐Ÿ‡ธ USA
LabCorp
LH
25.5-284.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Enzo Biochem
ENZB
-3.33-75.94%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.